Weight-Loss drug trial for pancreatic cancer halted early
NCT ID NCT04844970
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called anamorelin to see if it could help prevent weight loss and improve appetite in people with advanced pancreatic cancer who were starting chemotherapy. The trial planned to include about 100 participants but was stopped early after only 4 people enrolled. The drug was taken as a daily pill for 25 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lahey Hospital & Medical Center
Burlington, Massachusetts, 01805, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- A sound wave that could expose hidden pancreatic cancer?
- Can three common drugs boost chemotherapy against pancreatic cancer?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Smart drug delivers chemo directly to pancreatic cancer cells
- Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors